AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ribose-phosphate pyrophosphokinase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P11908

UPID:

PRPS2_HUMAN

Alternative names:

PPRibP; Phosphoribosyl pyrophosphate synthase II

Alternative UPACC:

P11908; Q0VDH9; Q0VDI0; Q15245; Q2TAK7

Background:

Ribose-phosphate pyrophosphokinase 2 (Ribose-PPK2), also known as PPRibP or Phosphoribosyl pyrophosphate synthase II, plays a pivotal role in nucleotide synthesis by catalyzing the formation of phosphoribosylpyrophosphate (PRPP). PRPP is a critical precursor for the biosynthesis of purines and pyrimidines, essential components of DNA and RNA.

Therapeutic significance:

Understanding the role of Ribose-phosphate pyrophosphokinase 2 could open doors to potential therapeutic strategies. Its fundamental involvement in nucleotide synthesis makes it a potential target for developing treatments for conditions where nucleotide balance is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.